{"id":41423,"date":"2018-10-17T09:52:35","date_gmt":"2018-10-17T13:52:35","guid":{"rendered":"http:\/\/blogs.uakron.edu\/researchnewsinfo\/?p=41423"},"modified":"2018-10-17T09:52:35","modified_gmt":"2018-10-17T13:52:35","slug":"dod-amyotrophic-lateral-sclerosis-research-program-pre-announcement","status":"publish","type":"post","link":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/2018\/10\/17\/dod-amyotrophic-lateral-sclerosis-research-program-pre-announcement\/","title":{"rendered":"DoD Amyotrophic Lateral Sclerosis Research Program Pre-announcement"},"content":{"rendered":"<p><strong>Defense Health Program<br \/>\nDepartment of Defense Amyotrophic Lateral Sclerosis Research Program<\/strong><\/p>\n<p><strong>Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>The FY19 Defense Appropriations Act provides $10 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP)<\/strong> to support innovative and high-impact research into preclinical development of therapeutics for Amyotrophic Lateral Sclerosis.\u00a0 As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&amp;E) appropriation.\u00a0 The managing agent for the anticipated Program Announcements\/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).<\/p>\n<p>The ALSRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.\u00a0 FY19 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in November 2018.\u00a0 Pre-application and application deadlines will be available when the Program Announcements are released.\u00a0 This pre-announcement should not be construed as an obligation by the government.<\/p>\n<p>The mission of the ALSRP is to fund innovative preclinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.<\/p>\n<p><a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=http%3A%2F%2Fcdmrp.army.mil%2Fpubs%2Fpress%2F2019%2F19alsrppreann&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=6TKT97j4i2xk77SSHpkvpu0S7AWGUtlcZP45bTcWrA8%3D&amp;reserved=0\">http:\/\/cdmrp.army.mil\/pubs\/press\/2019\/19alsrppreann<\/a><\/p>\n<p>The following mechanisms are planned for release:<\/p>\n<p><strong>Therapeutic Development Award<\/strong><\/p>\n<ul>\n<li>Independent investigators at all academic levels<\/li>\n<li><strong>Pre-application is required; full application submission is by invitation only<\/strong><\/li>\n<li>Supports post-discovery, preclinical advancement of therapeutics for ALS<\/li>\n<li>Preliminary data, including identity and purity of an identified bioactive compound(s), are required<\/li>\n<li>Clinical trials are not allowed<\/li>\n<li>Types of efforts that will be supported include:\n<ul>\n<li>Confirmation of candidate therapeutics obtained from screening or by other means<\/li>\n<li>Validation of early pilot studies in multiple model systems and\/or replicating preliminary data with more time points or additional doses<\/li>\n<li>Optimization of potency and pharmacology, studies of formulation, stability, and production methods based on Good Manufacturing Practices<\/li>\n<li>Investigational New Drug-enabling studies<\/li>\n<li><strong>Optional Therapeutic Relevance Option:<\/strong> Applications proposing development of markers to improve the drug development process in parallel with the main therapeutic advancement effort and that meet the criteria outlined in the Program Announcement\/Funding Opportunity will qualify for a higher level of funding<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li>Maximum funding of <strong>$1,000,000<\/strong> for direct costs (plus indirect costs)<\/li>\n<li>If applying for the <strong>Therapeutic Relevance Option,<\/strong> the maximum funding is <strong>$1,250,000<\/strong> for direct costs (plus indirect costs)<\/li>\n<li>Maximum period of performance is <strong>2\u00a0<\/strong>years<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Therapeutic Idea Award<\/strong><\/p>\n<ul>\n<li>Independent investigators at all academic levels<\/li>\n<li><strong>Pre-application is required; full application submission is by invitation only<\/strong><\/li>\n<li>Supports new ideas aimed at drug or treatment discovery that are still in the early stages of development<\/li>\n<li>Preliminary data are not required<\/li>\n<li>Types of efforts that will be supported include:\n<ul>\n<li>Exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and\/or advancing a novel treatment modality<\/li>\n<li>Development, modification, and use of high-throughput screens and novel model systems to define or assess lead compounds<\/li>\n<\/ul>\n<\/li>\n<li>Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this award mechanism<\/li>\n<li>Maximum funding of <strong>$500,000<\/strong> for direct costs (plus indirect costs)<\/li>\n<li>Maximum period of performance is <strong>2\u00a0<\/strong>years<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at <a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=https%3A%2F%2FeBRAP.org&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=MKzQNRDcQJ%2FEX3V7uJWZESJKN0noLdi3laWQjdfON88%3D&amp;reserved=0\">https:\/\/eBRAP.org<\/a> prior to the pre-application deadline.\u00a0 All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the <a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.grants.gov%2F&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=9dgRFuD87mAdgmSLQ4CBv3Y2EiQVzmpTjbmlTcPqpG0%3D&amp;reserved=0\">Grants.gov<\/a> website.\u00a0 The application package containing the required forms for each award mechanism will also be found on Grants.gov.\u00a0 A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.<\/p>\n<p>&nbsp;<\/p>\n<p>Applications must be submitted through the federal government\u2019s single-entry portal, <a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.grants.gov%2F&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=9dgRFuD87mAdgmSLQ4CBv3Y2EiQVzmpTjbmlTcPqpG0%3D&amp;reserved=0\">Grants.gov<\/a>.\u00a0 Submission deadlines are not available until the Program Announcements are released.\u00a0 For email notification when Program Announcements are released, subscribe to program-specific news and updates under \u201cEmail Subscriptions\u201d on the eBRAP homepage at <a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Febrap.org%2F&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=4qxZxJfv2U3piRDlKYAhYx01157PXbVQdKB8SRV2X20%3D&amp;reserved=0\">https:\/\/eBRAP.org<\/a>.\u00a0 For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (<a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=http%3A%2F%2Fcdmrp.army.mil%2F&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=CcG03vA4NBoHhNRg8QCV62vpdaZt%2FYVX22F3U356SWo%3D&amp;reserved=0\">http:\/\/cdmrp.army.mil<\/a>).<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Point of Contact:<\/strong><\/p>\n<p>CDMRP Public Affairs<br \/>\n301-619-9783<br \/>\n<strong><a href=\"mailto:usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil\">usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil<\/a><\/strong><\/p>\n<p>Book mark the CDMRP website:<\/p>\n<p>cdmrp.army.mil<\/p>\n<p>&nbsp;<\/p>\n<p>Follow CDMRP on Twitter at:<\/p>\n<p>twitter.com\/CDMRP<\/p>\n<p>View CDMRP research results on YouTube:<\/p>\n<p><a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=http%3A%2F%2Fwww.youtube.com%2Fuser%2FCDMRP&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=oOk843brw0NP9j6bSwHm06HBCPfa%2BDghR8oifKlK8IU%3D&amp;reserved=0\">www.youtube.com\/user\/CDMRP<\/a><\/p>\n<p>Like us on FaceBook:<\/p>\n<p><a href=\"https:\/\/na01.safelinks.protection.outlook.com\/?url=http%3A%2F%2Fwww.facebook.com%2FTheCDMRP&amp;data=02%7C01%7CRschSrvsGA8%40uakron.edu%7C3b223995f1f74dfe638d08d634376e1e%7Ce8575dedd7f94ecea4aa0b32991aeedd%7C1%7C0%7C636753810002963814&amp;sdata=bXg1QKZmZ3guwvK8KIQvKAyDr%2BPhdT%2BSMMfBwzPtMzc%3D&amp;reserved=0\">www.facebook.com\/TheCDMRP<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Defense Health Program Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2019 (FY19) \u00a0 The FY19 Defense Appropriations Act provides $10 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) &hellip; <a href=\"https:\/\/blogs.uakron.edu\/researchnewsinfo\/2018\/10\/17\/dod-amyotrophic-lateral-sclerosis-research-program-pre-announcement\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":3755,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-41423","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/posts\/41423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/users\/3755"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/comments?post=41423"}],"version-history":[{"count":1,"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/posts\/41423\/revisions"}],"predecessor-version":[{"id":41427,"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/posts\/41423\/revisions\/41427"}],"wp:attachment":[{"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/media?parent=41423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/categories?post=41423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.uakron.edu\/researchnewsinfo\/wp-json\/wp\/v2\/tags?post=41423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}